An open-label, single dose, crossover study to evaluate the relative bioavailability of a new fingolimod formulation (2 x 0.25 mg) in comparison to the Final Market Image (FMI, 0.5 mg) in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- 25 Feb 2013 Status changed from not yet recruiting to completed as reported by Clinical Trials Registry - India.
- 21 Jan 2012 New trial record